Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium glucose co‐transporter 2 (SGLT2) inhibitors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM). We examined the efficacy and safety of teneligliptin (a DPP‐4 inhibitor) added to canagliflozin (an SGLT2 inhibito...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes Obes Metab
Glavni autori: Kadowaki, Takashi, Inagaki, Nobuya, Kondo, Kazuoki, Nishimura, Kenichi, Kaneko, Genki, Maruyama, Nobuko, Nakanishi, Nobuhiro, Gouda, Maki, Iijima, Hiroaki, Watanabe, Yumi
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2017
Teme:
Brief Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5846888/
https://ncbi.nlm.nih.gov/pubmed/28786530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13079
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items